---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004245"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:21:47.944571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience closes initial tranche of Reg A offering at $5/unit; issues 5,090 units

## Summary
- Initial closing on Jan 27, 2026: issued 5,090 Units (each 1 share Series A Preferred + 2 warrants) for $25,450 gross proceeds.
- Series A Preferred convertible at $2.50/share, no dividends, liquidation preference $5/share, senior to common stock.
- Investor warrants exercisable at $4.00/share for 36 months; Agent warrants at $6.25/unit, subject to 180-day lock-up.
- Company can call preferred after 3 years at lesser of stated value + 8% annual or 200% of stated value.
- Forced conversion triggers: change of control, stock price ≥$4.50 for 10 of 30 days, or firm IPO ≥$15M at ≥$4.50.

## SEC filing metadata
- accession: 0001493152-26-004245
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.02, 8.01, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/0001493152-26-004245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004245
- JSON: https://secwatch.observer/filing/0001493152-26-004245.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004245.txt

## Source-grounded claims
- claim_id: 236467a7974ffbcaa76a0f4b0899d4375645b9a4
  claim: Dare Bioscience, Inc.: Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights (effective 2026-01-23).
  evidence_excerpt: On January 23, 2026, in anticipation of the initial closing of the Offering (as defined below), Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which became effective upon filing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/0001493152-26-004245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.